1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Chugai Pharmaceutical Co., Ltd
  6. News
  7. Summary
    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD

(4519)
  Report
Delayed Japan Exchange  -  12:08 2022-08-18 am EDT
3841.00 JPY   -0.98%
08/15CHUGAI PHARMACEUTICAL : Obtains Regulatory Approval for Osteoporosis Treatment Edirol Tablet
PU
08/11Chugai Pharmaceutical Co., Ltd. - Anti-C5 Recycling Antibody Crovalimab Obtains Priority Review in China for the Treatment of Paroxysmal Nocturnal Hemoglobinuria
AQ
08/10Roche's Rare Blood Disease Drug Wins Priority Review Tag In China
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Chugai Pharmaceutical Co., Ltd. Announces Changes in Representative Directors and Directors, Effective March 29, 2022

02/03/2022 | 03:00am EDT

Chugai Pharmaceutical Co., Ltd. announced changes in Representative Directors and Directors with the resolution of the Board of Directors Meeting held on February 3, 2022, as described below. The changes will be formalized after the Annual General Meeting of Shareholders and the Board of Directors Meeting scheduled on March 29, 2022. Since the conclusion of the strategic alliance agreement with Roche in 2001, the Company has been working diligently to establish a unique business model. In order to achieve sustainable growth and development of the Chugai group and further enhance the corporate value through promoting growth strategy "TOP I 2030" under a new management structure in 2022, Tatsuro Kosaka, Representative Director and Chairman, and Motoo Ueno, Representative Director and Deputy Chairman will retire, and Executive Vice Presidents, Hisafumi Yamada and Toshiaki Itagaki will be appointed as Directors. Name: Hisafumi Yamada, New Title: Director, Executive Vice President Supervisory responsibility for Project & Lifecycle Management (R&D), Research, Translational Research, Clinical Development, and Pharmaceutical Technology. Current Title: Executive Vice President Supervisory responsibility for Project & Lifecycle Management (R&D), Research, and Translational Research. Name: Toshiaki Itagaki, New Title: Director, Executive Vice President Chief Financial Officer (CFO) Supervisory responsibility for Finance & Accounting, Corporate Communication, and Purchasing Head of Finance Supervisory Div. Current Title: Executive Vice President Chief Financial Officer (CFO) Supervisory responsibility for Finance & Accounting, Corporate Communication, Purchasing, and Digital Transformation Head of Finance Supervisory Div. Effective Date: March 29, 2022.


© S&P Capital IQ 2022
All news about CHUGAI PHARMACEUTICAL CO., LTD
08/15CHUGAI PHARMACEUTICAL : Obtains Regulatory Approval for Osteoporosis Treatment Edirol Tabl..
PU
08/11Chugai Pharmaceutical Co., Ltd. - Anti-C5 Recycling Antibody Crovalimab Obtains Priorit..
AQ
08/10Roche's Rare Blood Disease Drug Wins Priority Review Tag In China
MT
08/10CHUGAI PHARMACEUTICAL : Anti-C5 Recycling Antibody Crovalimab Obtains Priority Review in C..
PU
08/09Chugai Pharmaceutical Co., Ltd. - Notice of the Settlement of Patent Infringement Litig..
AQ
08/08Chugai Pharmaceutical Co., Ltd. - Maruho Launched in Japan the Anti-IL-31 Receptor a Hu..
AQ
08/08CHUGAI PHARMACEUTICAL : Notice of the Settlement of Patent Infringement Litigation in the ..
PU
08/08Roche's Chugai Unit Launches Skin Disease Drug in Japan
MT
08/07CHUGAI PHARMACEUTICAL : Maruho Launched in Japan the Anti-IL-31 Receptor A Humanized Monoc..
PU
07/27Nikkei 225 Up 0.2% Ahead of Federal Reserve Announcement
MT
More news
Analyst Recommendations on CHUGAI PHARMACEUTICAL CO., LTD
More recommendations
Financials
Sales 2022 1 191 B 8 801 M 8 801 M
Net income 2022 347 B 2 565 M 2 565 M
Net cash 2022 518 B 3 829 M 3 829 M
P/E ratio 2022 18,4x
Yield 2022 2,05%
Capitalization 6 381 B 47 141 M 47 141 M
EV / Sales 2022 4,92x
EV / Sales 2023 5,40x
Nbr of Employees 7 664
Free-Float 38,0%
Chart CHUGAI PHARMACEUTICAL CO., LTD
Duration : Period :
Chugai Pharmaceutical Co., Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Last Close Price 3 879,00 JPY
Average target price 4 617,50 JPY
Spread / Average Target 19,0%
EPS Revisions
Managers and Directors
Tatsuro Kosaka Manager-Pharmaceutical Business Strategy Office
Osamu Okuda Manager-Life Cycle Management II
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CHUGAI PHARMACEUTICAL CO., LTD3.48%47 349
JOHNSON & JOHNSON-2.04%440 572
ELI LILLY AND COMPANY14.70%294 849
PFIZER, INC.-16.56%279 832
ROCHE HOLDING AG-16.74%273 886
ABBVIE INC.4.46%252 042